8 results match your criteria: "The Moscow Research and Clinical Center for Tuberculosis Control[Affiliation]"

Infections caused by nontuberculous mycobacteria (NTM) are rising globally throughout the world. The number of species isolated from clinical samples is steadily growing, which demands the implementation of a robust diagnostic method with wide specificity. This study was carried out in in 2022-2024 in three clinical antituberculosis centers in the biggest cities of Russia: Moscow, Saint Petersburg, and Novosibirsk.

View Article and Find Full Text PDF

The article reports on the rarest case of Guillain-Barré syndrome in the form of acute motor-sensory polyneuropathy in a female patient with tuberculous meningitis, disseminated pulmonary tuberculosis, and tuberculous pleurisy. In the neurological status at the exit from the coma, the patient was diagnosed with tetraplegia, bulbar syndrome, and respiratory disorders. Further, within a week, pronounced muscle atrophy appeared.

View Article and Find Full Text PDF

Perchlozone Resistance in Clinical Isolates of .

Antibiotics (Basel)

March 2023

Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.

The emergence of drug-resistant tuberculosis forced the development of new drugs and the screening of more effective or less toxic analogues. Mycolic acid biosynthesis is targeted by several antituberculosis drugs, isoniazid being one of the most important in tuberculosis therapy. Recently, perchlozone, acting on another step in the FAS-II cycle, was officially approved for tuberculosis treatment in the Russian Federation and was included in the Russian national clinical guidelines.

View Article and Find Full Text PDF

Molecular Determinants of Ethionamide Resistance in Clinical Isolates of .

Antibiotics (Basel)

January 2022

Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.

Background: Ethionamide and prothionamide are now included in group C of the WHO recommended drugs for the treatment of tuberculosis resistant to rifampicin and multidrug-resistant tuberculosis. The clinical relevance of ethionamide and prothionamide has increased with the wide spread of resistant tuberculosis.

Methods: We retrospectively analyzed 349 clinical isolates obtained between 2016 and 2020.

View Article and Find Full Text PDF

Genetic Profile of Linezolid-Resistant Clinical Strains from Moscow.

Antibiotics (Basel)

October 2021

Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.

Background: Linezolid, bedaquiline, and newer fluoroquinolones are currently placed as priority Group A drugs for the treatment of drug-resistant tuberculosis. The number of reported linezolid-resistant clinical strains is still low, and the correlation of molecular determinants with phenotype is not perfect.

Methods: We determined the linezolid MICs for clinical isolates from the Moscow region and identified mutations in and genes.

View Article and Find Full Text PDF

Reduced susceptibility and resistance to bedaquiline in clinical M. tuberculosis isolates.

J Infect

May 2020

Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia. Electronic address:

Objectives: Bedaquiline is an effective drug used to treat MDR and XDR tuberculosis, providing high cure rates in complex therapy. Mutations in the mmpR (rv0678) and atpE genes are associated with reduced susceptibility to bedaquiline and have been identified in both in vitro selected strains and clinical isolates. However, the phenotypic criteria used to detect bedaquiline resistance have yet to be established due to the collection of few clinical isolates from patients receiving bedaquiline-containing treatment regimens.

View Article and Find Full Text PDF
Article Synopsis
  • Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis pose significant global health challenges, exacerbated by a limited number of effective treatments that risk further drug resistance.
  • A study comparing MDR Mycobacterium tuberculosis isolates from Moscow and Taiwan found that Moscow had higher rates of pre-XDR and XDR strains, with only 3 effective drugs available for treatment compared to 7 in Taiwan.
  • The research indicates a pressing need for improved molecular testing methods to accurately detect a wider range of drug-resistant mutations, as a significant portion of isolates showed resistance to drugs like kanamycin, which traditional tests may miss.
View Article and Find Full Text PDF

Background: The goal of this study was to compare the consistency of three assays for the determination of the drug resistance of Mycobacterium tuberculosis (MTB) strains with various resistance profiles isolated from the Moscow region.

Methods: A total of 144 MTB clinical isolates with a strong bias toward drug resistance were examined using Bactec MGIT 960, Sensititre MycoTB, and a microarray-based molecular assay TB-TEST to detect substitutions in the rpoB, katG, inhA, ahpC, gyrA, gyrB, rrs, eis, and embB genes that are associated with resistance to rifampin, isoniazid, fluoroquinolones, second-line injectable drugs and ethambutol.

Results: The average correlation for the identification of resistant and susceptible isolates using the three methods was approximately 94%.

View Article and Find Full Text PDF